Using 64CU-DOTA-ECL1i PET Imaging to Detect CCR2 in Human Carotid and Femoral Artery Atherosclerosis Including Normal Volunteers and Patients Scheduled for Surgery or Medical Management

What this Trial Is About

Researchers are studying the use of a new radioactive imaging medicine called 64CU-DOTA-ECL1i to evaluate arterial atherosclerosis, which is the buildup of plaque in arteries. This study includes both healthy volunteers and patients with carotid or femoral artery disease. The aim is to better visualize and understand plaque in these arteries, especially in patients scheduled for surgery or managed medically. The study is a Phase 1 interventional trial conducted by Washington University School of Medicine. Participants are divided into two groups. Group 1 includes healthy volunteers and patients who will undergo surgery they receive a single imaging session lasting about 60 minutes with an injection of 64CU-DOTA-ECL1i to visualize their arteries. Plaque samples from surgery patients will be collected for further study. Group 2 consists of patients with artery disease who will not have surgery they will have two imaging sessions spaced 7 to 14 days apart to assess the imaging performance of the radioactive tracer. During the study, participants will undergo imaging using PET and MR cameras to evaluate the characteristics and performance of the 64CU-DOTA-ECL1i tracer over 1 to 2 days. The research team will monitor imaging results and collect relevant data related to arterial atherosclerosis. Safety and tolerability, including the ability to remain still during imaging, will be assessed, and the total participation duration varies depending on group and imaging schedule.

PET Detection of CCR2 in Human Atherosclerosis